INTERRUPTION and prevention of recurrent sustained ventricular tachycardia (VT) remains a therapeutic challenge because of the limitations of standard and investigational antiarrhythmic agents. In response to these limitations, a variety of cardiac surgical procedures and implantable electrical devices have been devised for termination of VT. 1' To date, no single antitachycardia pacing method has gained widespread acceptance and application because of technical limitations, lack of reproducibility, and the serious potential risk of acceleration of VT with resultant ventricular fibrillation. 5 The implantable cardioverter-defibrillator is a mode of terminating ventricular tachycardia-fibrillation in patients who are refractory to antiarrhythmic drugs and who are not candidates for, or have failed, cardiac surgical procedures. However, this method is not without problems; for the majority of patients who have symptomatic recurrent sustained VT without car-diac arrest, the internal defibrillator is by no means free of unacceptable and unpleasant side effects. Furthermore, faulty recognition of VT and inadvertent defibrillation continue with the present version of the implantable cardioverter-defibrillator. 6 Currently available modes of antitachycardia pacing include diastolic scanning with one to several extrastimuli and overdrive or burst pacing, which can be either automatic or activated by patient or physician with an external programmer.5 Recently an investigational implantable cardioverter has been used in patients with well-tolerated, slower VT.7 However, implantable antitachycardia pacers and cardioverters have achieved conversion efficacy rates ranging from only 30% to 80%, and an incidence of acceleration to decompensating VT and/or ventricular fibrillation has been observed in 35% to 43% of patients.3 4.6,7, -10 In 1976, Mandel et al.1' reported on a decremental implantable pacemaker for the termination of supraventricular tachycardia. This device was patient-activated with a magnet. In 1977 Waldo et al. 12 evaluated overdrive pacing for conversion of atrial flutter. These investigators described a technique of entrainment that involved manual decrement of the pacing cycle length (gradual increase in pacing rate) for the termination of this arrhythmia.
We have developed and tested an external beat-bybeat self-adapting autodecremental overdrive pacing system for termination of VT in patients with recurrent symptomatic ventricular tachyarrhythmias undergoing programmed ventricular stimulation and serial drug testing. With this device, we sought to test the hypothesis that this beat-by-beat autodecremental overdrive pacing method may be more effective and theoretically safer for the termination of VT. We compared this method to previously described antitachycardia pacing methods, in particular those used in commercially available implantable antitachycardia pacemakers.
Methods
Dysrhythmia Research Instrument for decremental pacing. The Dysrhythmia Research Instrument is an external programmable demand pacemaker (Medtronic Model 2319) that is computer controlled and can be programmed for self-adapting autodecremental demand pacing. The pacemaker recognizes VT through an indwelling right ventricular transvenous electrodes; it is programmed to recognize any tachycardia that has both an abrupt change in rate and a rate that exceeds the preset programmable tachycardia sensing rate (trigger interval). The pacemaker is set in demand pacing mode; when it senses the tachycardia for a programmable number of beats (e.g., 10), it initiates the antitachycardia treatment program in the following manner: At the onset of a pathologic tachycardia, the pacemaker's escape interval is shortened so that for the first paced beat it is identical to the cycle length of the tachycardia. Subsequently, it gradually overdrives the tachycardia beat-by-beat with a train of preprogrammed stimuli. Each interval in the train is decremented so that the pacemaker's beat-to-beat interval is continuously shortened by a programmable decrement measured in either milliseconds or by a percentage of the cycle length of the patient's VT. At the end of the initially programmed train of stimuli, the pacemaker reverts to its original backup demand pacing mode to protect against potential bradycardia after termination of VT. If the tachycardia is not terminated by the initial pacing train, the pacemaker again senses the pathologic tachycardia after a preset, programmable interval and repeats the beat-by-beat decremental pacing train, which is one beat longer than the initial train. This sequence, i.e., adding an additional beat to the train, is automatically and continuously repeated until the tachycardia is terminated or until a programmed maximum number of decremental stimuli in the train have been delivered. In this way, the program ensures that only a minimum number of decremental pacing stimuli are used to terminate the tachycardia. This pacemaker (Medtronic Model 2319), which is always in the demand pacing mode even during antitachycardia therapy, is linked to an HP85 computer with a tachycardia recognition algorithm and multiprogrammability.
The programmable variables in this external system are: beatby-beat decrements (msec or percentage of VT cycle length), number of autodecremental pacing stimuli (minimum/maximum), upper rate limit for decremental pacing, pacemaker output, sensitivity, pulse width, back-up demand pacing rate, tachycardia trigger interval, and number of intervals of tachycardia for recognition as a pathologic tachycardia.
Patient selection. Patients with a known history of clinical sustained VT or resuscitation from arrhythmic sudden cardiac death who underwent programmed ventricular stimulation with serial drug testing in our laboratory were selected for entrv into the study if, after induction of VT, they exhibited: (1) stable monomorphic VT of at least 30 sec duration requiring interruption and (2) VT that did not result in rapid hemodynamic decompensation requiring immediate cardioversion or defibrillation.
Patient demographics. This study was divided into three phases, and a total of 49 patients were exposed to self-adapting autodecremental overdrive pacing. The patients ranged in age from 25 to 80 years (mean 58 -+-11); there were 41 men and eight women. The predominant underlying disease in these patients was coronary artery disease with previous myocardial infarction (42 patients or 84%). Five patients (17%) had nonischemic congestive cardiomyopathy and two (5%) had idiopathic VT. The nuclear angiographic or contrast left ventricular ejection fractions of these patients ranged from 12% to 48% (mean 26 + 13%).
Autodecremental antitachycardia overdrive pacing. Learning/experience phase. In our initial evaluation of automatic (DOP), 15 patients satisfied the entrance criteria and had multiple episodes of VT exposed to DOP before and after antiarrhythmic therapy. When an "ideal" number of beats and the optimum beat-by-beat decrement was found that terminated VT, the arrhythmia was reinduced and reexposed to this program of DOP under the same conditions to establish reproducibility for termination of VT. In this way, both reproducibility and safety were established; success of DOP was considered to have occurred if VT was terminated on at least two consecutive occasions.
During these initial trials, the number of decrementing stimuli in the train (example five stimuli) and the beat-by-beat decrement (example 10 msec) were programmed manually. Subsequently, either the number of pacing stimuli or the beat-by-beat decrement was alternatively increased or decreased until a combination of the optimal pacing train and beat-by-beat decrement was established that reproducibly terminated each episode of induced VT. During this phase, the beat-by-beat decrement varied from 5 to 25 msec (mean 8.2) and the number of decremental pacing stimuli varied from five to 15 (mean 10.3).
Comparison of DOP and other antitachycardia pacing techniques. During this phase of evaluation, the DOP technique was compared with other antitachycardia pacing modalities that are incorporated into existing implantable pacing devices and/or are currently used in electrophysiologic laboratories for termination of induced VT. We induced VT successively on the same day, exposing each episode to one of several antitachycardia pacing methods, starting with DOP and following with diastolic scanning with single (S2) and/or double ventricular extrastimuli (S2S3). Subsequently, overdrive burst ventricular pacing was used, consisting of trains of five to 15 stimuli up to a cycle length of 200 msec.
In each patient an attempt was made, when possible, to reinduce VT and expose the arrhythmia to each of the four methods on at least two occasions on the same day or during the same interventional circumstances (antiarrhythmic agents). Because all patients were not able to tolerate multiple episodes of tachycardia and because VT acceleration developed at times, requiring cardioversion or defibrillation, not all patients were exposed to each of the methods of antitachycardia termination on the same day. When VT was not interrupted by any one of the methods, it was exposed arbitrarily to a second method while the tachycardia continued. If VT still persisted, the arrhythmia was exposed to the third method. During this phase the application of the three antitachycardia methods for interruption of VT was not randomized. External cardioversion was used only if all methods of antitachycardia pacing failed or if hemodynamic decompensation or acceleration occurred.
On the basis of our experience in phase I, we used pacing trains of five to 15 stimuli with a fixed beat-by-beat decrement of 10 msec for DOP.
Diastolic scanning (S2, S2S3) was applied with S2 initially inserted so that the SIS2 cycle length was 20 msec shorter than that of the SIS, cycle length. S2 was then scanned at 10 msec decrements until S2 reached SIS2 refractoriness. S2 was then fixed at 10 msec beyond refractoriness. Subsequently, S3 was inserted so that the S2S3 cycle length was equal to the S1S2 cycle length; S3 was then scanned at 10 msec decrements until it reached refractoriness in relation to S2.
Overdrive burst ventricular pacing involved calculation of the burst rate so that pacing trains (five to 15 stimuli) at least 25% faster than the patient's VT rate were used or until a cycle length of 200 msec was reached.
Self-adapting DOP vs overdrive burst pacing method (Fisher et al.3) . In the first two phases it was demonstrated that DOP could be effectively and safely applied to induced VT, especially when the VT cycle length was greater than or equal to 280 msec. Because the vast majority of patients amenable to antitachycardia pacing would fall into this range of VT cycle lengths, and with the knowledge that OD burst pacing is generally more efficacious than diastolic scanning with one or two extrastimuli from our phase II experience and that of others,3 we sought to compare DOP to overdrive burst pacing in the same 7x3.5O/o Decr. aVF VJ RVA HBE HBE patients. In this phase of the study, the VT in individual patients was exposed to either of the two methods in a random crossover fashion. The methods were compared during multiple VT inductions both before and during serial drug testing, and each method was tested on two consecutive induced episodes of VT.
During phases I and II of DOP evaluation, it became clear that decremental overdrive pacing was successful and safe and that the vast majority of VT episodes, especially those with cycle lengths of 280 msec or greater, could be interrupted by a train of pacing stimuli ranging from five to 15 with a decrement of 10 msec between beats. Based on the these data, an attempt was made to make the system adaptable to a variety of tachycardia rates by incorporating the VT cycle length into the program. Currently beat-by-beat decrements are calculated by the computer by multiplying the VT cycle length by 3.5%. With this modification decremental pacing is performed more gradually for the more rapid VTs, and the upper rate limit for pacing was set for safety reasons at 200 msec. As can be seen, larger decrements would occur in the slower VTs. In this way, automatic beat-by-beat decrements based on VT cycle length were made rather than fixing the decrement at 10 msec.
A further modification of the DOP program was effected if conversion of VT was not achieved: after an initial ineffective (VT persisting for 10 beats) train of five decremental pacing stimuli, automatically six decremental stimuli were delivered; if this failed then 7 beats of decremental pacing were administered and so on until either the tachycardia terminated or a train of 15 stimuli had been delivered. Once VT was terminated, the pacemaker reverted to its demand mode at 70 beats/min (programmable). At this point, the HP85 computer registered the number of stimuli that were required to terminate the VT. An example of VT termination with the automated DOP program can be seen in figure 1 Regarding safety, there were relatively few episodes of VT acceleration observed with all methods (3% to 11%); no statistically significant difference was observed between the different pacing methods.
Self-adapting autodecremental overdrive pacing vs overdrive burst pacing (Fisher et al.3 ). In the first two phases of the study, it became clear that the DOP method was more efficacious than the existing methods of interrupting VT, especially when it was applied to VT with cycle length of 280 msec or greater. In this third phase of the study, patients were exposed to both DOP and overdrive burst pacing (Fisher et In an attempt to identify an antitachycardia modality will, in general, influence the effectiveness of extrastimuli in invading the presumed reentry circuit. The decrease in local refractoriness that occurs after premature stimuli may allow for earlier activation of local tissues by subsequent stimuli, thereby explaining the effectiveness of burst pacing methods over single and double extrastimuli in terminating VT.s In an attempt to apply antitachycardia pacing in a slow progressive manner, we chose a beat-by-beat decremental pacing system that would serially scan a variety of pacing rates in a progressive and beat-by-beat manner, thereby incrementally peeling back refractoriness of myocardial tissues. This pacing protocol should progressively penetrate toward the reentry circuit; subsequent impulses would then transiently "entrain the reentry circuit."'2"-4 Insertion of progressively earlier stimuli should eventually result in invasion and interruption of the reentry circuit, presumably when both the antidromic and orthodromic pathways are depolarized by the same pacing stimulus with resultant collision and block (figure 3). 14 Thus the DOP method of scanning with a train of beats during one pacing sequence increases the likelihood that a critical rate for termination of VT will be achieved.3
Clinical implications. We currently use this automated form of DOP for termination of VT in our electrophysiology laboratory. In our experience, it is a more rapid technique than diastolic scanning with single, double, and triple extrastimuli. Moreover, it does not require manual measurement of VT rate or trial-and-error burst pacing at different rates and/or number of stimuli. As a result, it does not take longer to apply and to be effective for VT interruption. Because of its high efficacy rate and low incidence of VT acceleration, it has decreased the need for cardioversion and/or defibrillation during electrophysiologic studies in our laboratory. We believe that this method can be applied as the initial intervention in an implantable antitachycardia device for VT. Such a device would ideally incorporate backup internal defibrillation in the event the method should fail or result in VT acceleration.
